|Day Low/High||17.25 / 18.46|
|52 Wk Low/High||17.11 / 37.75|
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Nine biotech and drug companies want FDA approval, but need changed standards to get it.
The firms all have drugs they want the feds to bend the rules to approve.
Materials, financials, cyclicals and health care names tilt the scale to the bullish side.
Ask not for whom the register rings, and it better not ring for thee.
So much for the market opening flat. Futures took a tumble for the worse in the last hour before the open and equities are down across the board in early trading. The dollar is up nicely and oil is slightly down as we commence the last trading day o...
Sometimes, buying low can work as a balance, almost a strange sort of diversification.
The longer-term weekly chart is ugly, but optimistic in the near-term.
Shares of Acadia Pharmaceuticals (ACAD) popped over 25% this week after an FDA panel voted in favor of approving its drug for Parkinson's disease psychosis.
Shares of Alkermes (ALKS) were up 30 percent in 2015 and the biotech company’s strong pipeline for psychiatric drugs bodes well for another strong year in the market.
CAT not going down on bearish news gets us closer to a bottom and buy recommendation.
These four names stood out to me from a weekly perspective.
Each of these 'real' American firms is now a buyout candidate because of the ridiculous U.S. tax code.